Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer

Epidermal growth factor receptor (EGFR)‒tyrosine kinase inhibitors (TKIs) are effective clinical therapeutics for EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations. However, the vast majority of patients acquire resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jiyun, Shim, Joon Ho, Park, Woong-Yang, Kim, Hee Kyung, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333983/
https://www.ncbi.nlm.nih.gov/pubmed/29807405
http://dx.doi.org/10.4143/crt.2018.138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333983/
https://www.ncbi.nlm.nih.gov/pubmed/29807405
http://dx.doi.org/10.4143/crt.2018.138

Ejemplares similares